Cardiovascular Drugs and Therapy

, Volume 25, Issue 1, pp 77–85 | Cite as

Evaluation of the Functional Status Questionnaire in Heart Failure: A Sub-study of the Second Cardiac Insufficiency Bisoprolol Survival Study (CIBIS-II)

  • Siobhan Gallanagh
  • Davide Castagno
  • Ben Wilson
  • Erland Erdmann
  • Faiez Zannad
  • Willem J. Remme
  • José L. Lopez-Sendon
  • Philippe Lechat
  • Ferenc Follath
  • Christer Höglund
  • Viacheslav Mareev
  • Zygmunt Sadowski
  • Ricardo J. Seabra-Gomes
  • Henry J. Dargie
  • John J. V. McMurrayEmail author



We evaluated a generic quality of life (QoL) Functional Status Questionnaire (FSQ), in patients with chronic heart failure (CHF). The FSQ assesses the 3 main dimensions of QoL: physical functioning, mental health and social role. It also includes 6 single item questions about: work status, frequency of social interactions, satisfaction with sexual relationships, days in bed, days with restricted activity and overall satisfaction with health status. The FSQ was compared to the Minnesota Living with Heart Failure questionnaire (MLwHF).

Methods and results

The FSQ was evaluated in a substudy (n = 340) of the second Cardiac Insufficiency Bisoprolol Survival study (CIBIS-II), a placebo-controlled mortality trial. 265 patients (75%) patients completed both questionnaires at 6 months of follow-up. Both questionnaires indicated substantially impaired QoL. The FSQ demonstrated high internal consistency (Cronbach’s α > 0.7 for all items except “social activity” = 0.66) and construct and concurrent validity. After 6 months, the only item on either questionnaire to show a difference between the placebo- and bisoprolol-treatment groups was the single item FSQ question about “days in bed” (p = 0.018 in favour of bisoprolol).


The FSQ performed well in this study, provided additional information to the MLwHF questionnaire and allowed interesting comparisons with other chronic medical conditions. The FSQ may be a useful general QoL instrument for studies in CHF.

Key words

Heart failure Quality of life Functional status questionnaire Minnesota living with heart failure questionnaire 

Supplementary material

10557_2011_6284_MOESM1_ESM.doc (194 kb)
ESM 1 (DOC 194 kb)


  1. 1.
    Hobbs FDR, Kenkre JE, Roalfe AK, et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life. A cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J. 2002;23:1867–76.PubMedCrossRefGoogle Scholar
  2. 2.
    Jeunger J, Schellberg D, Kraemer S, et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart. 2002;87:235–41.CrossRefGoogle Scholar
  3. 3.
    Konstam V, Salem D, Pouleur H, et al. Baseline quality of life as a predictor of mortality and hospitalisation in 5025 patients with congestive heart failure. Am J Cardiol. 1996;78:890–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Lewis EF, Johnson PA, Johnson W, et al. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant. 2001;20:1016–24.PubMedCrossRefGoogle Scholar
  5. 5.
    Rector TS, Tschumperlin LK, Kubo SH, et al. Use of the Living with Heart Failure Questionnaire to ascertain patients’ perspectives on improvement in quality of life versus risk of drug-induced death. J Card Fail. 1995;1:201–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Berry C, McMurray J. A review of quality-of-life evaluations in patients with congestive heart failure. Pharmacoeconomics. 1999;16:247–71.PubMedCrossRefGoogle Scholar
  7. 7.
    Rector TS, Kubo SH, Cohn JN. Patient’s self assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure: the Minnesota Living with Heart Failure questionnaire. Heart Fail. 1987;3:198–219.Google Scholar
  8. 8.
    Jette AM, Davies AR, Cleary PD, et al. The Functional Status Questionnaire: reliability and validity when used in primary care. J Gen Intern Med. 1986;1:143–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Soderback I, Schult ML, Nordemar R. Assessment of patients with chronic back pain using the Functional Status Questionnaire. Scand J Rehab Med. 1993;25:139–43.Google Scholar
  10. 10.
    Bostrom C, Harms-ringdahl K, Nordemar R. Relationships between measurements of impairment, disability, pain and disease activity in rheumatoid arthritis patients with shoulder problems. Scand J Rheumatol. 1995;24:352–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Jette DU, Manago D, Medved E, et al. The disablement process in patients with pulmonary disease. Phys Ther. 1997;77:385–94.PubMedGoogle Scholar
  12. 12.
    Rubenstein LM, Voelker MD, Christchilles EA, et al. The usefulness of the functional status questionnaire and the medical outcomes study short form in Parkinson’s disease research. Qual Life Res. 1998;7:279–90.PubMedCrossRefGoogle Scholar
  13. 13.
    Murphy N, Confavreux C, Haas J, et al. Quality of life in multiple sclerosis in France, Germany and the United Kingdom. J Neurol Neurosurg Psychiatry. 1998;65:460–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Tedesco C, Manning S, Lindsay R, et al. Functional assessment of elderly patients after percutaneous aortic balloon valvuloplasty: New York Heart Association classification versus functional status questionnaire. Heart Lung. 1990;19:118–25.PubMedGoogle Scholar
  15. 15.
    Riedinger MS, Dracup KA, Brecht M, et al. Quality of life in patients with heart failure: do gender differences exist? Heart Lung. 2001;30:105–16.PubMedCrossRefGoogle Scholar
  16. 16.
    Investigators CIBIS-II. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.CrossRefGoogle Scholar
  17. 17.
    Design of the cardiac insufficiency bisoprolol study II (CIBIS II). The CIBIS II Scientific Committee. Fundam Clin Pharmacol. 1997; 11:138–42Google Scholar
  18. 18.
    Lewis EF, Lamas GA, O’Meara E, et al. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail. 2007;9:83–91.PubMedCrossRefGoogle Scholar
  19. 19.
    Cleland JGF, Calvert MJ, Verboven Y, et al. Effects of cardiac resynchronization therapy on long-term quality of life: An analysis from the Cardiac Resynchronisation-Heart Failure (CARE-HF) study. Am Heart J. 2009;157:457–66.PubMedCrossRefGoogle Scholar
  20. 20.
    Majani G, Giardini A, Opasich C, et al. Effect of Valsartan on quality of life when added to Usual Therapy for Heart Failure: results from the Valsartan Heart Failure Trial. J Card Fail. 2005;11:253–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure the metoprolol CR/XL randomized intervention trial in Congestive Heart Failure (MERIT-HF). JAMA. 2000;283:1295–302.PubMedCrossRefGoogle Scholar
  22. 22.
    Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail. 1997;3:173–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Yarnold PR, Stille FC, Martin GJ. Cross-sectional psychometric assessment of the functional status questionnaire: use with geriatric versus nongeriatric ambulatory medical patients. Int J Psychiatry Med. 1995;25:305–17.PubMedCrossRefGoogle Scholar
  24. 24.
    Rubenstein LM, Voelker MD, Christchilles EA, et al. The usefulness of the functional status questionnaire and the medical outcomes study short form in Parkinson’s disease research. Qual Life Res. 1998;7:279–90.PubMedCrossRefGoogle Scholar
  25. 25.
    Jette DU, Manago D, Medved E, et al. The disablement process in patients with pulmonary disease. Phys Ther. 1997;77:385–94.PubMedGoogle Scholar
  26. 26.
    Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996;942:800–6.Google Scholar
  27. 27.
    Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective randomized evaluation of carvedilol on symptoms and exercise. Circulation. 1996;94:2793–9.PubMedGoogle Scholar
  28. 28.
    Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995;25:1225–31.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Siobhan Gallanagh
    • 1
  • Davide Castagno
    • 1
    • 2
  • Ben Wilson
    • 1
  • Erland Erdmann
    • 3
  • Faiez Zannad
    • 4
  • Willem J. Remme
    • 5
  • José L. Lopez-Sendon
    • 6
  • Philippe Lechat
    • 7
  • Ferenc Follath
    • 8
  • Christer Höglund
    • 9
  • Viacheslav Mareev
    • 10
  • Zygmunt Sadowski
    • 11
  • Ricardo J. Seabra-Gomes
    • 12
  • Henry J. Dargie
    • 13
  • John J. V. McMurray
    • 1
    Email author
  1. 1.BHF Glasgow Cardiovascular Research CentreUniversity of GlasgowGlasgowUK
  2. 2.Cardiology Unit, Department of Internal MedicineUniversity of TurinTurinItaly
  3. 3.Department III of Internal MedicineUniversity of CologneCologneGermany
  4. 4.University of NancyNancyFrance
  5. 5.Sticares Cardiovascular Research InstituteRhoonNetherlands
  6. 6.Department of CardiologyUniversity Hospital La PazMadridSpain
  7. 7.Pharmacology Department, Pitié-Salpêtrière Hospital, APHP, UPMCParisFrance
  8. 8.University Hospital ZürichZürichSwitzerland
  9. 9.Stockholm Heart CentreStockholmSweden
  10. 10.Myasnikow Institute of CardiologyMoscowRussia
  11. 11.National Institute of CardiologyWarsawPoland
  12. 12.Cardiology DepartmentSanta Cruz HospitalCarnaxidePortugal
  13. 13.Golden Jubilee National Hospital, ClydebankGlasgowUK

Personalised recommendations